Latest Graft Versus Host Disease News

Page 6 of 6

Mesoblast Secures A$260M to Propel Ryoncil® US Launch and Clinical Trials

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.

Ada Torres

14 Jan 2025

Browse the archive

Full archive

Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026